US EPA

9807580 

Journal Article 

Review 

MANAGEMENT OF ENDOCRINE DISEASE Clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategiesClinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies 

Raverot, G; Jouanneau, E; Trouillas, J 

2014 

Yes 

European Journal of Endocrinology
ISSN: 0804-4643
EISSN: 1479-683X 

170 

4 

R121-R132 

English 

24431196 

10.1530/EJE-13-1031 

WOS:000334351800002 

Pituitary tumours, the most frequent intracranial tumour, are historically considered benign. However, various pieces of clinical evidence and recent advances in pathological and molecular analyses suggest the need to consider these tumours as more than an endocrinological disease, despite the low incidence of metastasis. Recently, we proposed a new prognostic clinicopathological classification of these pituitary tumours, according to the tumour size (micro, macro and giant), type (prolactin, GH, FSH/LH, ACTH and TSH) and grade (grade 1a, non-invasive; 1b, non-invasive and proliferative; 2a, invasive; 2b, invasive and proliferative and 3, metastatic). In addition to this classification, numerous molecular prognostic markers have been identified, allowing a better characterisation of tumour behaviour and prognosis. Moreover, clinical and preclinical studies have demonstrated that pituitary tumours could be treated by some chemotherapeutic drugs or new targeted therapies. Our improved classification of these tumours should now allow the identification of prognosis markers and help the clinician to propose personalised therapies to selected patients presenting tumours with a high risk of recurrence.